This compound is not intended for human consumption, clinical use, or therapeutic application of any kind
Given the essential role of astrocytes in the hippocampal neurogenic niche in the control of neurogenesis (Song et al., 2002), it is tempting to speculate that dynamic promoter methylation might regulate expression of these Fgfs and contribute to the regulation of adult hippocampal neurogenesis

Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists
This means it helps hydrate the skin
Together, they provide a synergistic effect that promotes skin health, hydration, and rejuvenation